Sudarshan Pharma Industries Ltd files revised SAST disclosure for Hemal Vasantrai Mehta

What Sudarshan Pharma announced

Sudarshan Pharma Industries Ltd (BSE: 543828) lodged a revised disclosure with the Bombay Stock Exchange on 14 July 2026. The filing is made under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 and relates to Hemal Vasantrai Mehta. The company did not provide additional quantitative details such as the number of shares held or the monetary value of the acquisition.

Revised Disclosure under SEBI (SAST) Regulations

The revised disclosure replaces an earlier filing concerning the same shareholder. Regulation 31(1) requires a target entity to disclose any acquisition that results in a person or group holding 25% or more of its voting share capital, while Regulation 31(2) mandates disclosure of any change in the shareholding pattern that could affect control. The filing confirms compliance with these statutory obligations but remains silent on the exact shareholding percentage or the price paid.

"The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 on July 14, 2026 for Hemal Vasantrai Mehta."

Key facts at a glance

Why this matters for investors

The filing signals that a shareholder, Hemal Vasantrai Mehta, has reached a threshold that triggers mandatory disclosure under SEBI’s takeover code. While the exact size of the stake is not disclosed, the requirement itself suggests a potentially material holding. Investors should monitor subsequent filings for the original and any future disclosures that may reveal the precise share percentage, transaction price, or any related agreements. Such information could affect voting dynamics, board composition, or future strategic decisions.

Conclusion

Sudarshan Pharma has complied with SEBI’s SAST disclosure requirements by submitting a revised notice concerning Hemal Vasantrai Mehta on 14 July 2026. The filing does not provide quantitative details, and further disclosures may be required to fully illuminate the impact of this shareholding on the company’s governance and capital structure.